OraSure Technologies, Inc. (OSUR) Stock

OraSure Technologies, Inc. operates as a pioneering company specializing in the development, manufacturing, marketing, and sale of oral fluid diagnostic products and specimen collection devices globally. With a presence in the United States, Europe, and beyond, the company operates through two primary segments: Diagnostics and Molecular Solutions.

Among its flagship offerings are a suite of rapid tests including the InteliSwab COVID-19 rapid test series tailored for different applications, such as professional use, prescription use, and broader rapid testing needs. Additionally, OraSure Technologies is renowned for its OraQuick line, encompassing HIV tests for both clinical and in-home use, as well as innovative products like the OraQuick HCV rapid antibody test and the OraQuick Ebola rapid antigen test. These products are supported by the OraSure oral fluid collection device, integral for HIV-1 antibody screening and confirmation.

The company also provides Intercept drug testing systems, immunoassay tests, reagents, and a variety of genomic products under the Oragene and ORAcollect brands, facilitating comprehensive genomics laboratory services and microbiome collection. Further enhancing its portfolio, OraSure Technologies offers cutting-edge molecular testing solutions through its ORAcollect, RNA and OMNIgene, and RAL collection devices, pivotal in COVID-19 diagnostics and beyond.

OraSure Technologies serves a broad spectrum of clients including clinical laboratories, hospitals, clinics, public health organizations, government agencies, and commercial entities. With a commitment to advancing healthcare through innovation, the company continues to lead in the field of diagnostic technologies. Established in 2000 and headquartered in Bethlehem, Pennsylvania, OraSure Technologies remains at the forefront of transforming how diseases are detected and managed globally.